The global healthcare contract sales organizations market size was valued at USD 12.9 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2032.
Report Scope of the Healthcare Contract Sales Organizations Market:
|Market Size in 2022||USD 12.9 billion|
|Revenue Forecast by 2032||USD 29.17 billion|
|Growth rate from 2023 to 2032||8.5%|
|Report coverage||Revenue forecast, company share, competitive landscape, growth factors & trends|
The healthcare contract sales organizations market is witnessing growth due to various factors. One of the key factors driving the growth is the increasing number of new drug launches and the increase in pharmaceutical R&D activities. The biopharmaceutical pipeline is also growing, with over 45% of the total drugs in the pipeline being biopharmaceuticals. Lastly, the growing demand to reduce the cost associated with in-house sales is also driving the adoption of contract sales services. Contract sales organizations provide a cost-effective solution for pharmaceutical companies to promote and sell their products without incurring the high cost of maintaining an in-house sales team. All these factors are supporting the growth of the Healthcare CSO Market.
The COVID-19 pandemic has led to significant changes in the way that pharmaceutical sales activities are carried out, due to restrictions on physical visits to healthcare professionals' offices. As a result, remote communication channels such as web conferences, phone, email, and website engagement have become increasingly important for facilitating sales. This has led to an increase in the adoption of new technologies in pharmaceutical contract sales. According to a Hexaware survey from 2020, 43% of healthcare professionals limited or prevented visits from pharma representatives, with 28% indicating that these restrictions for medical representative visits would be permanent. Looking ahead, it is projected that more than 70% of activities will occur through digital mediums in a post-COVID-19 world. To stay competitive in this changing landscape, Healthcare Contract Sales Organizations must adapt to this new engagement model by equipping their sales teams with the necessary digital tools and technology to better understand customer needs in a hybrid or remote setting. Additionally, CSOs must operate within agile, self-sustaining feedback loops to remain competitive.
As the COVID-19 pandemic continues to recede, healthcare CSOs are facing a new reality. The post-COVID-19 world has ushered in a new era of remote sales activities, which require organizations to adapt their engagement models and sales strategies. In a hybrid or remote setting, digital tools and technologies have become essential for CSOs to gain a deeper understanding of customer needs, deliver effective communication and collaboration, and foster strong customer relationships. Therefore, organizations need to focus on investing in technology solutions that enable them to optimize their sales processes, analyze customer data, and provide personalized and effective experiences.
Over the last five years, the pharmaceutical industry has seen a surge in drug launches, coupled with regulatory scrutiny and increased competition among healthcare companies. Consequently, the demand for intense sales has grown, even as the traditional model of sales representatives visiting individual doctors is changing due to shifting promotional preferences and evolving provider habits. These factors are expected to drive the demand for contract sales services among healthcare companies, thereby promoting market growth.
Key Companies & Market Share Insights
Market players are undertaking various strategic initiatives such as collaborations, partnerships, geographic expansions, and mergers and acquisitions aiming to strengthen their service portfolio, to provide a competitive advantage. For instance, Arecor Therapeutics plc's subsidiary, Tetris Pharma Ltd, announced a service agreement with Syneos Health in December 2022 to expand its commercial platform across Europe. Through this partnership, Syneos Health will provide outsourced contract sales services to support the launch of Tetris Pharma's flagship product, Ogluo, for diabetes patients in the initial launch territories. The collaboration is expected to increase healthcare practitioner awareness of the product and support its commercial success in the region. Some prominent players in the global healthcare contract sales organizations market are:
Healthcare Contract Sales Organizations Market Segmentation: